AstraZeneca PLC
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Other Medicines (Established / Legacy Brands) by Quarter
Other Medicines (Established / Legacy Brands) — Worldwide YoY actual (%) (%)
AstraZeneca Other Medicines (Established / Legacy Brands): -4.0% in Q2 2026, up 6.0 pts from a year earlier.
Where the Q2 2026 figure comes from
“|| Other Medicines | | 230 | | ( 4 ) | | ( 6 ) | | 19 | | ( 9 ) | | 166 | | ( 10 ) | | ( 13 ) | | 25 | | 52 | | 51 | | 20 | | 12 | | 14”
Source: Form 6-K FY2026Q2 Earnings Release ↗
Reported in Form 6-K / 20-F Therapy Area Product Sales Table.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Other Medicines (Established / Legacy Brands) — Worldwide YoY actual (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | -4.0% | +6.0 pts | Form 6-K FY2026Q2 Earnings Release ↗ |
| Q1 2026 | Mar 31, 2026 | -7.0% | +2.0 pts | Form 6-K FY2026Q1 Earnings Release ↗ |
| Q4 2025 | Dec 31, 2025 | -7.0% | -1.0 pts | Form 6-K FY2025Q4 Earnings Release ↗ |
| Q3 2025 | Sep 30, 2025 | -12.0% | -1.0 pts | Form 6-K FY2025Q3 Earnings Release ↗ |
| Q2 2025 | Jun 30, 2025 | -10.0% | +1.0 pts | Form 6-K FY2025Q2 Earnings Release ↗ |
| Q1 2025 | Mar 31, 2025 | -9.0% | -3.0 pts | Form 6-K FY2025Q1 Earnings Release ↗ |
| Q4 2024 | Dec 31, 2024 | -6.0% | +24.0 pts | Form 6-K FY2024Q4 Earnings Release ↗ |
| Q3 2024 | Sep 30, 2024 | -11.0% | +16.0 pts | Form 6-K FY2024Q3 Earnings Release ↗ |
| Q2 2024 | Jun 30, 2024 | -11.0% | +17.0 pts | Form 6-K FY2024Q2 Earnings Release ↗ |
| Q1 2024 | Mar 31, 2024 | -6.0% | +20.0 pts | Form 6-K FY2024Q1 Earnings Release ↗ |
| Q4 2023 | Dec 31, 2023 | -30.0% | -23.0 pts | Form 6-K FY2023Q4 Earnings Release ↗ |
| Q3 2023 | Sep 30, 2023 | -27.0% | -44.0 pts | Form 6-K FY2023Q3 Earnings Release ↗ |
| Q2 2023 | Jun 30, 2023 | -28.0% | -25.0 pts | Form 6-K FY2023Q2 Earnings Release ↗ |
| Q1 2023 | Mar 31, 2023 | -26.0% | -7.0 pts | Form 6-K FY2023Q1 Earnings Release ↗ |
| Q4 2022 | Dec 31, 2022 | -7.0% | -20.0 pts | Form 6-K FY2022Q4 Earnings Release ↗ |
| Q3 2022 | Sep 30, 2022 | 17.0% | +44.0 pts | Form 6-K FY2022Q3 Earnings Release ↗ |
| Q2 2022 | Jun 30, 2022 | -3.0% | +16.0 pts | Form 6-K FY2022Q2 Earnings Release ↗ |
| Q1 2022 | Mar 31, 2022 | -19.0% | -17.0 pts | Form 6-K FY2022Q1 Earnings Release ↗ |
| Q4 2021 | Dec 31, 2021 | 13.0% | +1.0 pts | Form 6-K FY2021Q4 Earnings Release ↗ |
| Q3 2021 | Sep 30, 2021 | -27.0% | – | Form 6-K FY2021Q3 Earnings Release ↗ |
| Q2 2021 | Jun 30, 2021 | -19.0% | – | Form 6-K FY2021Q2 Earnings Release ↗ |
| Q1 2021 | Mar 31, 2021 | -2.0% | – | Form 6-K FY2021Q1 Earnings Release ↗ |
| Q4 2020 | Dec 31, 2020 | 12.0% | – | Form 6-K FY2020Q4 Earnings Release ↗ |
Cite this data
StockData. (2026). AstraZeneca Other Medicines (Established / Legacy Brands) (%), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/ta-other-meds-world-act-yoy
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.